Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab Biomarker Study in HS and AD
NCT06524635Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lutikizumab in hidradenitis suppurativa (HS), atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Aug 2024; status: recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06524635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524635.